>
Switch to:

Horizon Therapeutics Revenue per Share

: $11.08 (TTM As of Jun. 2021)
View and export this data going back to 2011. Start your Free Trial

Horizon Therapeutics's revenue per share for the three months ended in Jun. 2021 was $3.54. Horizon Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2021 was $11.08.

During the past 12 months, the average Revenue Per Share Growth Rate of Horizon Therapeutics was 51.30% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 16.40% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 11.90% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 31.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Horizon Therapeutics's Revenue per Share or its related term are showing as below:

NAS:HZNP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.9   Med: 19.3   Max: 115.5
Current: 16.4

-9.9
115.5

During the past 13 years, Horizon Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 115.50% per year. The lowest was -9.90% per year. And the median was 19.30% per year.

NAS:HZNP's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 115 Companies
in the Drug Manufacturers industry.

( Industry Median: 7.40 vs. NAS:HZNP: 16.40 )

Horizon Therapeutics Revenue per Share Historical Data

The historical data trend for Horizon Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Revenue per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.11 6.48 7.27 6.34 10.22

Horizon Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Revenue per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.40 2.84 3.17 1.53 3.54

Horizon Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Horizon Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2020 is calculated as

Revenue Per Share (A: Dec. 2020 )=Revenue (A: Dec. 2020 )/Shares Outstanding (Diluted Average) (A: Dec. 2020 )
=2200.429/215.309
=10.22

Horizon Therapeutics's Revenue Per Share for the quarter that ended in Jun. 2021 is calculated as

Revenue Per Share (Q: Jun. 2021 )=Revenue (Q: Jun. 2021 )/Shares Outstanding (Diluted Average) (Q: Jun. 2021 )
=832.548/235.192
=3.54

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Horizon Therapeutics  (NAS:HZNP) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Horizon Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics Business Description

Horizon Therapeutics logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, 1st Floor, Dublin, IRL, D04 C5Y6
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.
Executives
Sherman Jeffrey W officer: EVP and Chief Medical Officer C/O IDM PHARMA, INC. 9 PARKER, SUITE 100 IRVINE CA 92618
Camardo Daniel A. officer: EVP and President, U.S. C/O HORIZON THERAPEUTICS, PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 D04 C5Y6
Konstantinovsky Irina officer: EVP, Chief Human Resources Off C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Beeler Brian K officer: EVP, General Counsel C/O HORIZON PHARMA PLC 520 LAKE COOK ROAD, SUITE 520 DEERFIELD IL 60015
Hoelscher Paul W. officer: EVP, CFO 520 LAKE COOK ROAD, SUITE 520 C/O HORIZON PHARMA, INC. DEERFIELD IL 60062
Walbert Timothy P director, officer: Chairman, President and CEO 1033 SKOKIE BOULEVARD SUITE 355 NORTHBROOK IL 60062
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Santini Gino director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Karnani Vikram officer: EVP & President, International C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE 1ST FLOOR, 1 BURLINGTON RD DUBLIN L2 4
Witz Pascale director C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121
Shannon James Samuel director 28903 NORTH AVENUE PAINE VALENCIA CA 91355
Kent Jeff officer: See remarks C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Moze Barry officer: EVP, Chief Admin. Officer C/O HORIZON PHARMA, INC. 520 EAST COOK ROAD, SUITE 520 DEERFIELD IL 60015
Mchugh Miles W officer: Sr VP & Princ. Acctg Officer C/O ACCRETIVE HEALTH, INC. 401 N. MICHIGAN AVE, SUITE 2700 CHICAGO IL 60611
Curtis Geoffrey M. officer: EVP, Corporate Affairs, CCO C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 L2 4

Horizon Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)